Delisting risk
Cellectar Biosciences
Develops targeted radiotherapeutics for cancer through a phospholipid drug conjugate platform.
$2.60
After-hours close+0.09 (+3.39%)
At close$2.51(−0.99%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 3.89%310.7K sharesInsiders 0.59%47.2K sharesOther 95.52%7.63M shares
Shares outstanding 7.99M · Float 7.50M · 93.8% free float
Institutions13F, as of Mar 31, 2026
19 holders · 310.7K shares · 4 new positions · 6 increased · 3 reduced · 5 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Bleichroeder LP | 100.0K | 1.25% | 0 | May 14, 2026 |
| Vanguard Capital Management LLC | 81.9K | 1.02% | +81.9Knew | May 15, 2026 |
| Geode Capital Management, LLC | 52.8K | 0.66% | +24.1K | May 15, 2026 |
| Sequoia Financial Advisors, LLC | 18.9K | 0.24% | −6.5K | Apr 30, 2026 |
| Vanguard Fiduciary Trust Co | 16.6K | 0.21% | +16.6Knew | May 8, 2026 |
| Warberg Asset Management LLC | 13.9K | 0.17% | 0 | May 7, 2026 |
| Riverview Capital Advisers, LLC | 10.4K | 0.13% | 0 | May 14, 2026 |
| UBS Group AG | 9.6K | 0.12% | +7.0K | May 5, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Balyasny Asset Management L.P. | 9.99% | 798.4K | 13G | Aug 14, 2026 ↗ |
| SilverArc Capital Management, LLC | 9.99% | 851.3K | 13G | Aug 14, 2026 ↗ |
| Bleichroeder LP | 9.99% | 808.3K | 13G | Aug 13, 2026 ↗ |
| Empery Asset Management, LP | 9.99% | 864.1K | 13G | Aug 4, 2026 ↗ |
| Janus Henderson Group PLC | 9.99% | 798.4K | 13G | Jun 5, 2026 ↗ |
| StemPoint Capital LP | 9.90% | 845.7K | 13G | Aug 14, 2026 ↗ |
| Stonepine Capital Management, LLC | 9.90% | 863.3K | 13G | May 11, 2026 ↗ |
| Lytton Laurence W | 8.80% | 13G | Feb 13, 2025 ↗ | |
| Caligan Partners LP | 5.90% | 470.0K | 13G | Aug 14, 2026 ↗ |
| Nantahala Capital Management, LLC | 5.73% | 13G | Feb 14, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Jarrod Longcor | officer: Chief Operating Officer | 20.5K | 0.26% | May 11, 2026 |
| James V. Caruso | director, officer: Chief Executive Officer | 20.3K | 0.25% | May 11, 2026 |
| Chad J. Kolean | officer: Chief Financial Officer | 6.4K | 0.08% | Jul 3, 2025 |
| John Neis | director | 10 | 0.00% | Dec 16, 2025 |
4 ten-percent owners hold 306 shares by Form 4, outside the officers-and-directors figure above · 11 people have not refiled in the last 18 months (3.5K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| May 7, 2026 | James V. Carusodirector, officer: Chief Executive Officer | Purchase · 2 lots | 34,720 | $2.88 | 56,394 |
| May 7, 2026 | Jarrod Longcorofficer: Chief Operating Officer | Purchase · 2 lots | 34,720 | $2.88 | 56,600 |
| Dec 12, 2025 | John Neisdirector | Sale | 198 | $3.70 | 10 |
CongressHouse and Senate disclosures
Not reported.